

PRESS RELEASE

Correction: Hansa Biopharma Nomination Committee formed

The correction only concerns the removal of the reference to the EU Market Abuse Regulation that was incorrectly included in the original press release, distributed at 8am on December 23, 2022.

Lund, December 28, 2022. Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on June 30, 2022 and has the following composition:

- Natalie Berner representing Redmile Group
- Jannis Kitsakis representing AP4
- Arne Myhrman representing Thomas Olausson

As the conveyer of the Nomination Committee, Peter Nicklin, Chairman of the Board of Directors at Hansa Biopharma will be asked to summon the first meeting in the Nomination Committee.

The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of the chairman of the AGM, election of auditors (if applicable) and fee for the auditors, and proposals for rules for appointing the Nomination Committee.

The proposals of the Nomination Committee will be presented in the notice of the Annual General Meeting 2023 and will be published on Hansa Biopharma's website.

Shareholders wishing to submit comments or proposals to the Nomination Committee may do so via e-mail to ir@hansabiopharma.com or by letter to Hansa Biopharma, Nomination Committee, Box 785, 220 07 Lund, Sweden.

--ENDS--

For more information:

Klaus Sindahl, *Head of Investor Relations*

M: +46 (0) 709-298 269

E: klaus.sindahl@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving, and life-altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy, and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <https://hansabiopharma.com>.